Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Long-Term Debt Repayments (2018 - 2019)

X4 Pharmaceuticals (XFOR) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $6.5 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Long-Term Debt Repayments rose 1190.8% year-over-year to $6.5 million, compared with a TTM value of $6.5 million through Dec 2020, down 45.46%, and an annual FY2023 reading of $2.1 million, up 159.62% over the prior year.
  • Long-Term Debt Repayments was $6.5 million for Q3 2019 at X4 Pharmaceuticals, up from $4.9 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $6.5 million in Q3 2019 and bottomed at $500000.0 in Q1 2018.